2. Signaling Pathways
  3. Stem Cell/Wnt
  4. β-catenin
  5. β-catenin Antagonist

β-catenin Antagonist

β-catenin Antagonists (4):

Cat. No. Product Name Effect Purity
  • HY-109103
    Tegatrabetan
    		Antagonist 99.77%
    Tegatrabetan (BC2059) is a β-Catenin antagonist. Tegatrabetan disrupts the binding of β-catenin with the scaffold protein transducin β-like 1 (TBL1).
  • HY-101486
    LF3
    		Antagonist 99.55%
    LF3 is an antagonist of the β-Catenin/TCF4 interaction with antitumor activity; has an IC50 of 1.65 μM.
  • HY-N7702
    N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide
    		Antagonist 98.05%
    N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide is a macamide isolated from Maca (Lepidium meyenii Walp.) N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide induces mesenchymal stem cells osteogenic differentiation and consequent bone formation through activating the canonical Wnt/β‐catenin signaling pathway. N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide can be used for the research of osteoporosis.
  • HY-160765
    WNTinib
    		Antagonist
    WNTinib (APS-8-100-2) is a multi-kinase inhibitor that selectively antagonizes β-catenin (CTNNB1) mutated hepatocellular carcinoma (HCC). WNTinib downregulates oncogenicWntsignaling by inhibiting KIT/MAPK and downstream EZH2 activation.